Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon

And I bet your hospital did nothing with all this earlier research either.

• DMT (8 posts to November 2020)

• ecstasy (19 posts to November 2012)

• LSD (5 posts to Serptember 2018)

• magic mushrooms (10 posts to October 2014) 

  psilocybin (14 posts to May 2014)

  • 
    

   

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.

AGNPF

has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands. 

CEO Christopher J. Moreau said the company is thrilled to initiate its clinical stroke research program with this study as “preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor which is an important part of the brain’s recovery process after an injury like a stroke.”

The trial, to be conducted at the Centre for Human Drug Research (CHDR) in Leiden, is expected to open enrollment shortly and dose the first participant in December 2022.